Significance of age in acute myeloid leukemia patients younger than 30 years: A common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A

Cancer

Volumn 112, Issue 3, 2008, Pages 562-571

  Creutzig, Ursula ^a,d   Büchner, Thomas ^a   Sauerland, Maria C ^a   Zimmermann, Martin ^b   Reinhardt, Dirk ^b   Döhner, Hartmut ^c   Schlenk, Richard F ^c  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Acute myeloid leukemia; Adolescents; Age; Childhood; Prognostic factors; Young adults

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; RETINOL; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLAST CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL COUNT; CHILD; CLINICAL TRIAL; DRUG MEGADOSE; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADULT; AGING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLAST CRISIS; BONE MARROW; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CYTARABINE; ETOPOSIDE; FEMALE; HUMANS; IDARUBICIN; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; PROGNOSIS; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 38849113944     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23220     Document Type: Article

References (40)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2000. Available from URL: http://seer.cancer.gov/csr/1975_2000 Accessed on March 12, 2007.
2. Büchner T, Heinecke A. The role of prognostic factors in acute myeloid leukemia. Leukemia. 1996;10(Suppl 1):S28-S29.
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med. 1985;103:626-629.
4. Bennett JM, Catovsky D, Daniel MT, et al. Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:460-462.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325-329.
6. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15:348-354.
7. Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia. 2005;19:2030-2042.
8. Creutzig U, Zimmermann M, Lehrnbecher T, et al. Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98. J Clin Oncol. 2006;24:4499-4506.
9. Büchner T, Hiddemann W, Berdel WE, et al. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol. 2003;21:4496-4504.
10. Büchner T, Berdel WE, Schoch C, et al. Double induction containing either 2 courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol. 2006;24:2480-2489.
11. Schlenk RF, Benner A, Hartmann F, et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial. Leukemia. 2003;17:1521-1528.
12. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004;22:3741-3750.
13. Schlenk RF, Dohner K, Pralle H, et al. Risk-adapted therapy in younger adults with acute myeloid leukemia: results of the AMLHD98A trial of the AMLSG. Blood. 2006;108. Abstract 14.
14. Vormoor J, Ritter J, Creutzig U, et al. Acute myelogenous leukaemia in children under 2 years - experiences of the West German AML Studies BFM-78, -83 and -87. Br J Cancer. 1992;66(suppl XVIII):63-67.
15. Schoch C, Kern W, Kohlmann A, et al. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer. 2005;43:227-238.
16. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions and response in acute myeloid leukemia. J Clin Oncol. 1990;8:813-819.
17. Korn EL. Censoring distributions as a measure of follow-up in survival analysis. Stat Med. 1986;5:255-260.
18. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630-639.
19. Jeha S, Smith FO, Estey E, et al. Comparison between pediatric acute myeloid leukemia (AML) and adult AML in VEGF and KDR (VEGF-R2) protein levels. Leuk Res. 2002;26:399-402.
20. Steinbach D, Furchtbar S, Sell W, et al. Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML. Leukemia. 2003;17:470-471.
21. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood. 2006;108:63-73.
22. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173-4179.
23. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312-1320.
24. Fröhling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280-3288.
25. Stiller CA, Benjamin S, Cartwright RA, et al. Patterns of care and survival for adolescents and young adults with acute leukaemia - a population-based study. Br J Cancer. 1999;79:658-665.
26. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19:2025-2029.
27. Schoch C, Kern W, Schnittger S, et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89:1082-1090.
28. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003;21:774-780.
29. Sallan SE. Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program. 2006;128-132.
30. Woods WG, Alonzo TA, Lange BJ, et al. Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): a comparison of outcomes between patients treated on childhood or adult protocols. Blood. 2001;98:462a-463a, Abstract 1934.
31. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003;101:64-70.
32. Razzouk BI, Estey E, Pounds S, et al. Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer. 2006;106:2495-2502.
33. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council's 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89:2311-2318.
34. Horibe K, Tsukimoto I, Ohno R. Clinicopathologic characteristics of leukemia in Japanese children and young adults. Leukemia. 2001;15:1256-1261.
35. Penson RT, Rauch PK, McAfee SL, et al. Between parent and child: negotiating cancer treatment in adolescents. Oncologist. 2002;7:154-162.
36. Bleyer A. Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am. 2002;49:1027-1042.
37. Bleyer WA, Tejeda H, Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997;21:366-373.
38. Lie SO, Jonmundsson G, Mellander L, et al. A population-based study of 272 children with acute myeloid leukaemia treated on two consecutive protocols with different intensity: best outcome in girls, infants, and children with Down's syndrome. Nordic Society of Paediatric Haematology and Oncology (NOPHO). Br J Haematol. 1996;94:82-88.
39. Creutzig U, Henze G, Bielack S, et al. Krebserkrankungen bei Kindern: Erfolg durch einheitliche Therapiekonzepte seit 25 Jahren. Dtsch Arztebl. 2003;100:A842-A852.
40. Benjamin S, Kroll ME, Cartwright RA, et al. Haematologists' approaches to the management of adolescents and young adults with acute leukaemia. Br J Haematol. 2000;111:1045-1050.